E.R. Pfefferkorn

Composite genome map and recombination parameters derived from three archetypal lineages of Toxoplasma gondii

Toxoplasma gondii is a highly successful protozoan parasite in the phylum Apicomplexa, which contains numerous animal and human pathogens. T.gondii is amenable to cellular, biochemical, molecular and genetic studies, making it a model for the biology of this important group of parasites. To facilitate forward genetic analysis, we have developed a high-resolution genetic linkage map for T.gondii. The genetic map was used to assemble the scaffolds from a 10X shotgun whole genome sequence, thus defining 14 chromosomes with markers spaced at ∼300 kb intervals across the genome. Fourteen chromosomes were identified comprising a total genetic size of ∼592 cM and an average map unit of ∼104 kb/cM. Analysis of the genetic parameters in T.gondii revealed a high frequency of closely adjacent, apparent double crossover events that may represent gene conversions. In addition, we detected large regions of genetic homogeneity among the archetypal clonal lineages, reflecting the relatively few genetic outbreeding events that have occurred since their recent origin. Despite these unusual features, linkage analysis proved to be effective in mapping the loci determining several drug resistances. The resulting genome map provides a framework for analysis of complex traits such as virulence and transmission, and for comparative population genetic studies.

Interferon-γ suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan

The effect of human recombinant interferon-gamma (IFN-gamma) on Toxoplasma gondii in cultured human fibroblasts is predominantly parasitostatic. This effect is dependent upon the induction in the host cell of a potent indoleamine 2,3-dioxygenase that converts tryptophan to N-formylkynurenine. This product is, in turn, degraded to kynurenine by a formamidase. Within 24 h of treatment with IFN-gamma most of the tryptophan originally present in the medium is converted to these products together with some minor metabolites. When added to the medium of infected cultures at concentrations equimolar to the tryptophan content, neither N-formylkynurenine nor kynurenine suppresses the growth of T. gondii, although at higher concentrations they are effective. The medium of uninfected cultures treated with IFN-gamma for 24 h has no effect on the growth of T. gondii, when transferred to fresh cultures provided that the residual IFN-gamma is first removed by ultrafiltration or neutralized with a specific monoclonal antibody. Thus minor metabolites produced from tryptophan in response to IFN-gamma and excreted into the medium are not parasitostatic. When cultures treated with IFN-gamma for 24 h are incubated with medium that contains [3H]tryptophan, the radioactive amino acid is converted to N-formylkynurenine and kynurenine as rapidly as it enters the cell. This degradation not only results in a very low intracellular concentration of tryptophan but also produces intracellular concentrations of tryptophan metabolites that are significantly higher than the tryptophan concentration in control cells. However, it is unlikely that either metabolite reaches intracellular concentrations that are sufficient to suppress the growth of the parasite. The parasitostatic effect of IFN-gamma is most likely to result from the starvation of T. gondii for tryptophan.

Pyrimidine synthesis by intracellular Toxoplasma gondii.

Pyrimidine biosynthesis was studied in actively dividing, intracellular Toxoplasma gondii, in mutant Chinese hamster ovary cells blocked in pyrimidine biosynthesis to eliminate any contribution by the host cell. The parasite grew normally in these cells even though pyrimidines were not supplied in the medium. Uninfected, mutant cultures showed negligible pyrimidine synthesis. However, mutant cultures infected wit T. gondii efficiently incorporated 14C from glucose or aspartic acid into the pyrimidine bases of nucleic acids. Thus T. gondii is capable of de novo pyrimidine biosynthesis. The parasite may also be able to use pyrimidines of the host cell, because of pyrazofurin, an antimetabolite that blocks pyrimidine biosynthesis, markedly inhibited only a mutant parasite defective in the salvage of pyrimidines.

Reproduction of Togaviruses

The togaviruses may be more familiar to some readers under the old term “arboviruses.” Arboviruses (arthropod-borne), as originally defined, generally are transmitted to their vertebrate hosts by the bite of an infected arthropod, usually a mosquito or a tick. In this natural cycle, the arthropod does not play a passive role; instead, active multiplication of virus in the arthropod host is essential. As Casals (1971) has pointed out, this essentially ecological classification no longer suffices to define a morphologically and biochemically related group of viruses and hence should be abandoned.

MUTANTS OF TOXOPLASMA GONDII RESISTANT TO ATOVAQUONE (566C80) OR DECOQUINATE

Mutants of Toxoplasma gondii resistant to drugs that appear to affect the mitochondrial bc1 complex were isolated with the aid of mutagenesis with ethylnitrosourea. Mutant DeqR-1 was > 1,000-fold more resistant to decoquinate than was the wild type but more sensitive to atovaquone (formerly called 566C80). Mutant AtoR-1 was 20-fold more resistant to atovaquone than was the wild type and was also partially cross-resistant to decoquinate. Both drugs rapidly inhibited oxygen uptake by freshly prepared extracellular parasites, and the mutants were resistant to this inhibition. Neither the addition of uracil to the medium nor the use of a mutant of T. gondii with a defect in pyrimidine salvage had a substantial effect on the in vitro anti-parasitic activity of these drugs, suggesting that de novo pyrimidine synthesis was not the major biochemical target of either drug.

[1] Forward and reverse genetics in the study of the obligate, intracellular parasite Toxoplasma gondii

Publisher Summary This chapter describes methodologies for both forward genetics—(i.e., conventional and transmission genetics) and reverse genetics (transfection/transformation). The study of parasitic protozoa has benefited relatively little from the application of genetics. In part, this is because most of the organisms that have been models for biochemical and molecular analyses do not lend themselves to such approaches. In many cases, no sexual cycle is known and culture methods are so cumbersome that in vitro manipulations are extremely difficult. One exception to both these limitations is the apicomplexan protozoan, Toxoplasma gondii . It has long been known that toxoplasma is capable of unlimited asexual growth as a haploid form in almost any warm-blooded vertebrate. The inherent potential for using genetics to understand the biology of toxoplasma is now beginning to be realized. There is, however, much to be done. Among the major challenges are the development of stable plasmid replicons, physical maps of chromosomes, more detailed genetic maps, sequence tag sites or similar efficient, high density markers, catalogued cosmid or yeast artificial chromosome banks that allow moving from a given genetic location direction to the genomic region of interest, and methods for in vitro crosses.

Toxoplasma gondii: Genetic crosses reveal phenotypic suppression of hydroxyurea resistance by fluorodeoxyuridine resistance

Mutants resistant to sinefungin (SF) and hydroxyurea (HU) were isolated from an oocyst-producing strain of Toxoplasma gondii with the aid of mutagenesis with ethylnitrosourea. These mutants were used with previously described mutants resistant to adenine arabinoside (araA) and fluorodeoxyuridine (FUDR) in genetic crosses in cats. In order to interpret the data from crosses in which all four mutants were used to infect the same cat, it was necessary to devise a mathematical expression to predict the recombination frequency for unlinked markers. This frequency was shown in theory to be half of the product of the two parental phenotype frequencies. A series of crosses in which the parental frequencies were systematically varied yielded frequencies of recombination that were in accord with this calculation. The four-way crosses in the same cat showed unlinked recombination between all markers except HU and FUDR. This pair of markers yielded no doubly resistant recombinants, suggesting complete linkage. However, linkage was excluded when a binary cross between the HU- and FUDR-resistant mutants resulted in the normal number of doubly sensitive recombinants. The lack of doubly resistant recombinants was shown to be a consequence of phenotypic suppression of HU resistance by FUDR resistance. This suppression was first demonstrated by showing that an FUDR-resistant mutant selected from an HU-resistant parasite lost the HU resistance. The phenotypically suppressed HU-resistant gene was revealed by genetic crosses with wild type T. gondii. Although both parental stains were sensitive to HU, some of the progeny parasites were resistant.

Toxoplasma gondii: Characterization of a mutant resistant to sulfonamides

Sulfadiazine was a potent inhibitor of the in vitro growth of Toxoplasma gondii, although it had little effect during the first 24 hr of treatment. A mutant parasite (R-SulR-5) with a 300-fold increase in sulfadiazine resistance was selected by a combination of chemical mutagenesis and growth in gradually increased sulfadiazine concentrations. This mutant was completely cross-resistant to several other sulfonamides and to dapsone. The same concentration of p-aminobenzoic acid reversed the sulfadiazine inhibition of both mutant and wild-type parasites even though much higher concentrations of sulfadiazine were used to inhibit the mutant. Dihydropteroate synthase, a sulfonamide-sensitive enzyme in the pathway leading to dihydrofolic acid, had similar activities in wild-type and R-SulR-5 parasites. However, the mutant enzyme was 40-fold more resistant to sulfadiazine and had higher apparent Kms for both substrates, p-aminobenzoic acid and dihydropteridine pyrophosphate. The mutant was slightly less active than the wild type in the uptake of sulfadiazine.

Toxoplasma gondii: in vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide.

The anticoccidial drug arprinocid and arprinocid-N-oxide, a metabolite produced in vivo, blocked the growth of Toxoplasma gondii in human fibroblasts. The more potent arprinocid-N-oxide inhibited growth by 50% at 20 ng/ml while arprinocid inhibited at 2 micrograms/ml. For both drugs, the host cell was less sensitive than was the parasite. Hypoxanthine did not reverse the antitoxoplasma activity of either drug. We isolated a parasite mutant, R-AnoR-1 that was 16- to 20-fold more resistant to arprinocid-N-oxide than was the wild type RH T. gondii. This mutant was not resistant to arprinocid in vitro. Arprinocid in a daily oral dose of 136 micrograms regularly protected mice against an otherwise fatal infection with RH T. gondii and 55 micrograms had some protective effect. However, all mice infected with R-AnoR-1 and treated with 360 micrograms arprinocid per day died. Since this mutant is fully sensitive to arprinocid, the form of the drug that is therapeutically active in vivo cannot be arprinocid and is likely to be arprinocid-N-oxide.

Development of genetic systems for Toxoplasma gondii

The protozoan parasite Toxoplasma gondii has recently emerged as an important opportunistic pathogen in humans. Toxoplasma also shares a number of biological features with Plasmodium and Eimeria, which are important pathogens of humans and animals. Because o f the ease o f experimental use, David Sibley, Elmer Pfefferkom and John Boothroyd have undertaken the development of genetics in Toxoplasma as a model intracellular parasite. Toxoplasma is presently the only parasitic protozoan where both classical and molecular genetics are feasible. The recent advances in this system are highlighted here, along with potential applications of genetics for understanding intracellular parasitism.